Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 May 2008

Gryshchenko Irina, Hofbauer Sebastian, Stoecher Markus, Daniel Peter T, Steurer Michael, Gaiger Alexander, Eigenberger Karin, Greil Richard, Tinhofer Inge

Abstract excerpt

PURPOSE: A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has been negatively associated with onset and outcome of disease in solid tumors. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL), we assessed the role of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to Immunoglobulin Heavy Chains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Variable Region

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Membrane Glycoproteins

Share to Proto-Oncogene Proteins c-mdm2

Share to Survival Rate

Share to ZAP-70 Protein-Tyrosine Kinase

Source

Identifiers

PMID: 18467716
DOI: 10.1200/JCO.2007.11.5212

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.PMID 18467716Read ↗

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.Semantic proximity Read ↗

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Semantic proximity Read ↗

Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.Semantic proximity Read ↗

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Semantic proximity Read ↗

Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.